Deciphera Pharmaceuticals Overview
- Year Founded
-
2003
- Status
-
Acquired/Merged
- Employees
-
400
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2.4B
Deciphera Pharmaceuticals General Information
Description
Developer of kinase-inhibiting drugs designed to treat cancer and immunological diseases.The company offers a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors, enabling patients living with cancer to access transformative therapies that aim to improve their quality of life.
Contact Information
Website
www.deciphera.com(Operating Subsidiary)
Corporate Office
- 200 Smith Street
- Waltham, MA 02451
- United States
Corporate Office
- 200 Smith Street
- Waltham, MA 02451
- United States
Deciphera Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 11-Jun-2024 | $2.4B | Completed | Generating Revenue | ||
| 9. 2PO | 24-Jan-2023 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Private | 12-Aug-2020 | Completed | Generating Revenue | |||
| 7. Secondary Transaction - Open Market | Completed | Clinical Trials - Phase 1 | ||||
| 6. Secondary Transaction - Open Market | 13-Feb-2020 | Completed | Clinical Trials - Phase 1 | |||
| 5. 2PO | 11-Jun-2018 | Completed | Clinical Trials - Phase 1 | |||
| 4. IPO | 28-Sep-2017 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series C) | 05-Jun-2017 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series B) | 05-Jan-2016 | $90M | $90M | Completed | Generating Revenue | |
| 1. Grant | 18-Jul-2011 | $4.99M | Completed | Generating Revenue |
Deciphera Pharmaceuticals Comparisons
Industry
Financing
Details
Deciphera Pharmaceuticals Competitors (84)
One of Deciphera Pharmaceuticals’s 84 competitors is Blueprint Medicines, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Day One Biopharmaceuticals | Formerly VC-backed | Brisbane, CA | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| OncoResponse | Venture Capital-Backed | Houston, TX |
Deciphera Pharmaceuticals Patents
Deciphera Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026212999-A1 | Processes for making ulk inhibitors | Pending | 31-Mar-2025 | ||
| WO-2026165163-A1 | Cdk inhibitors and methods of use thereof | Pending | 30-Jan-2025 | ||
| WO-2026136733-A1 | Cdk inhibitors and methods of use thereof | Pending | 20-Dec-2024 | ||
| WO-2026136890-A1 | Formulations of ulk inhibitors | Pending | 20-Dec-2024 | ||
| WO-2026136890-A9 | Formulations of ulk inhibitors | Pending | 20-Dec-2024 | A61K31/553 |
Deciphera Pharmaceuticals Signals
Deciphera Pharmaceuticals Former Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Altamont Pharmaceutical Holdings | Holding Company | Minority | ||
| Brinker Capital | Asset Manager | Minority | ||
| Colorado Public Employees' Retirement Association | Corporation | Minority | ||
| Ensign Peak Advisors | Corporation | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority |
Deciphera Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated February, 28, 2025
25.41 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Pharmaceuticals
Subindustry
of 394
Rank
Percentile
Deciphera Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Redmile Deciphera Holdings | San Francisco, CA | 2019 |
Deciphera Pharmaceuticals FAQs
-
When was Deciphera Pharmaceuticals founded?
Deciphera Pharmaceuticals was founded in 2003.
-
Where is Deciphera Pharmaceuticals headquartered?
Deciphera Pharmaceuticals is headquartered in Waltham, MA.
-
What is the size of Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals has 400 total employees.
-
What industry is Deciphera Pharmaceuticals in?
Deciphera Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Deciphera Pharmaceuticals a private or public company?
Deciphera Pharmaceuticals is a Private company.
-
What is the current valuation of Deciphera Pharmaceuticals?
The current valuation of Deciphera Pharmaceuticals is .
-
What is Deciphera Pharmaceuticals’s current revenue?
The current revenue for Deciphera Pharmaceuticals is .
-
How much funding has Deciphera Pharmaceuticals raised over time?
Deciphera Pharmaceuticals has raised $414M.
-
Who are Deciphera Pharmaceuticals’s investors?
Altamont Pharmaceutical Holdings, Brinker Capital, Colorado Public Employees' Retirement Association, Ensign Peak Advisors, and Frazier Healthcare Partners are 5 of 15 investors who have invested in Deciphera Pharmaceuticals.
-
Who are Deciphera Pharmaceuticals’s competitors?
Blueprint Medicines, Aura Biosciences, Day One Biopharmaceuticals, Ability Pharma, and OncoResponse are some of the 84 competitors of Deciphera Pharmaceuticals.
-
When was Deciphera Pharmaceuticals acquired?
Deciphera Pharmaceuticals was acquired on 11-Jun-2024.
-
Who acquired Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals was acquired by ONO Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process